THERAPEUTIC COMBINATIONS OF TDFRPs AND ADDITIONAL AGENTS AND METHODS OF USE

Abstract

The present disclosure relates generally to methods of treating or preventing a tissue differentiation factor-associated disorder or disease and methods of treating or preventing fibrosis in a subject using tissue differentiation factor related polypeptide (TDFRPs) in combination with an additional agent. The present disclosure also relates to compositions and pharmaceutical compositions comprising the TDFRPs and an additional agent.

1 . A method of treating or preventing a tissue differentiation factor-associated disorder or disease, the method comprising: administering to a subject in need of treatment at least one tissue differentiation factor related polypeptide (TDFRP) in combination with an additional agent, wherein the additional agent is selected from the group consisting of: an inhibitor of angiotensin converting enzyme (ACE), a neprilysin inhibitor and an angiotensin receptor-neprilysin inhibitor, wherein the TDFRP and additional agent are administered in an amount effective to treat or prevent the tissue differentiation factor-associated disorder or disease in the subject. 
     
     
         2 . The method of  claim 1 , wherein the serum half-life of the TFDRP is increased when administered with the additional agent, compared to administration of the TDFRP alone. 
     
     
         3 . The method of  claim 2 , wherein serum half-life is increased between about 5-fold to about 10-fold or more when the TDFRP is administered with the additional agent. 
     
     
         4 . The method of  claim 1 , wherein the tissue differentiation factor-associated disorder or disease is selected from a tissue degenerative disease or disorder or a tissue regeneration disease or disorder. 
     
     
         5 . The method of  claim 4 , wherein the tissue regeneration disease or disorder is selected from the group consisting of a disease or disorder of the kidney or renal tissue, a disease or disorder of the heart or cardiovascular system, a disease or disorder of the liver or hepatic system, and cancer. 
     
     
         6 .- 15 . (canceled) 
     
     
         16 . The method of  claim 4 , wherein the tissue degenerative disease or disorder is selected from the group consisting of renal disease, macular degeneration, degenerative joint disease, traumatic brain or spinal cord injury, stroke, atherosclerosis, arthritis, emphysema, osteoporosis, cardiomyopathy, cirrhosis, degenerative nerve disease, Holt-Oram disease, eye disease, diabetic nephropathy, degenerative bone disease, liver disease, periodontal disease, diabetes, cardiovascular disease, inflammatory disease, immune disease, skeletal disease, reproductive disease, haematopoietic disease, cellular damage due to ionizing radiation, cellular damage due to hypoxia and cancer. 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . A method of treating or preventing a disease or disorder associated with fibrosis in a subject, the method comprising administering to a subject in need of treatment at least one TDFRP in combination with an additional agent, wherein the additional agent is selected from the group consisting of: an inhibitor of angiotensin converting enzyme (ACE), a neprilysin inhibitor and an angiotensin receptor-neprilysin inhibitor, wherein the TDFRP and additional agent are administered in an amount effective to treat the fibrosis in the subject. 
     
     
         20 . The method of  claim 19 , wherein the fibrosis is selected from the group consisting of: pulmonary fibrosis, renal fibrosis and hepatic fibrosis. 
     
     
         21 .- 24 . (canceled) 
     
     
         25 . The method of  claim 1 , wherein the TDFRP is a Multiple Domain TDFRP. 
     
     
         26 . The method of  claim 1 , wherein the angiotensin converting enzyme (ACE) inhibitor is selected from the group consisting: of captopril, zofenopril, enalapril, ramipril, quinapril, perindopril, lisinopril, benazepril, imidapril, trandolapril, fosinopril, moexipril, cilazapril, spirapril, temocapril, allacepril, ceronapril, delepril, moveltipril, and combinations thereof. 
     
     
         27 . The method of  claim 1 , , wherein the neprilysin inhibitor is selected from the group consisting of: thiorphan, candoxatril, and candoxatrilat. 
     
     
         28 . The method of  claim 1 , wherein the angiotensin receptor-neprilysin inhibitor is sacubitril/valsartan. 
     
     
         29 .- 33 . (canceled) 
     
     
         34 . The method of  claim 1 , further comprising the administration of a therapeutic agent selected from the group consisting of: anti-neoplastic agents, antibiotics, vaccines, immunosuppressive agents, anti-hypertensive agents and mediators of the hedgehog signaling pathway. 
     
     
         35 . A method of increasing the serum half-life of a tissue differentiation factor related polypeptide (TDFRP) in a subject, the method comprising: administering to the subject at least one tissue differentiation factor related polypeptide (TDFRP) in combination with an additional agent, wherein the additional agent is selected from the group consisting of: an inhibitor of angiotensin converting enzyme (ACE), a neprilysin inhibitor and an angiotensin receptor-neprilysin inhibitor, wherein administration of the TDFRP and additional agent increases the serum half-life of the TDFRP compared to administration of the TDFRP alone. 
     
     
         36 . (canceled) 
     
     
         37 . The method of  claim 35 , wherein serum half-life is increased about 5-fold to about 10-fold or more when the TDFRP is administered with the additional agent. 
     
     
         38 . (canceled) 
     
     
         39 . The method of  claim 35 , wherein the subject has a tissue differentiation factor-associated disorder or disease or a disease or disorder associated with fibrosis. 
     
     
         40 . (canceled) 
     
     
         41 . A composition comprising at least one TDFRP and an additional agent, wherein the additional agent is selected from the group consisting of: an inhibitor of angiotensin converting enzyme (ACE), a neprilysin inhibitor and an angiotensin receptor-neprilysin inhibitor. 
     
     
         42 . A pharmaceutical composition comprising the composition of  claim 41  and a pharmaceutical excipient. 
     
     
         43 . A kit comprising the pharmaceutical composition of  claim 42  and instructions for use in treating or preventing a tissue differentiation factor-associated disorder or disease, or instructions for use in treating or preventing fibrosis in a subject. 
     
     
         44 . (canceled)